US · Healthcare · Biotechnology
EPS came in at 0.47 against a street estimate of 0.83 — a miss of 43.4%.
Analysts rate Vir Biotechnology Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $21.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.22% |
| ARCH VENTURE CORP | 7.50% |
| Vanguard Portfolio Management, LLC | 6.79% |
| SB INVESTMENT ADVISERS (UK) LTD | 6.47% |
| State Street Corp | 5.89% |
| GSK PLC | 5.05% |
| Vanguard Capital Management, LLC | 3.78% |
| Point72 Asset Management, L.P. | 3.35% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 HEADLINE NUMBERS • On October 8, 2026, the FDA granted Fast Track designation to VIR-5500. • VIR-5500 is being developed for late-line metastatic ca | 2026-10-08 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Aziz Sawaf, MBEE, MBA, CFA, has been appointed Executive Vice President and Chief Financial Officer and principal financial office | 2026-10-01 |
| Quarterly report · Q2 2026 VIR BIOTECHNOLOGY, INC. – Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash & Investments: $1.01 billion in total (cash/equivalents $278.7M + short- | 2026-08-05 |
| Results announced · Q3 2026 VIR BIOTECHNOLOGY Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $1.01 billion as of June 30, 2026 (up | 2026-08-05 |
| Board / officer change · Q3 2026 VIR BIOTECHNOLOGY, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial results or numerical business metrics provided in this filing • Document | 2026-07-24 |
| Board / officer change · Q2 2026 VIR BIOTECHNOLOGY, INC. - DOCUMENT SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company is a biotechnology firm headquartered in San Francisco, Californi | 2026-06-10 |
| Board / officer change · Q2 2026 VIR BIOTECHNOLOGY, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of March 31, 2026: 161,234,058 common shares • Board size: Decre | 2026-05-28 |
| Quarterly report · Q1 2026 VIR BIOTECHNOLOGY, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Loss Q1 2026: $125.7 million (vs. $121.0 million Q1 2025) • Net Loss Per Share | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| Global strategic collaboration with Gilead includes $25 million strategic equity investment Vir Biotechnology entered a global collaboration with Gilead to discover and engineer three potential cancer drugs using PRO-XTEN dual-masked T-cell engager technology, aimed at selected sol | 2026-10-14 |
| Strategic partnership and equity investment with Astellas announced Vir Biotechnology announced Q4 2025 and full-year 2025 financial results on February 23, 2026. The company also disclosed an equity investment from Astellas (a major pharmaceutical partner) | 2026-02-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vir Biotechnology Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.